切换导航

GDC-0941

现货
Catalog No.
A8210
PI3K抑制剂
组合的产品项目
规格价格库存 数量
10mM (in 1mL DMSO)
¥ 550.00
现货
10mg
¥ 500.00
现货
50mg
¥ 750.00
现货
200mg
¥ 2,100.00
现货

电话: 021-55669583

邮箱: sales@apexbio.cn

全球经销商

Background

GDC-0941 is a novel selective class I phosphatidylinositol-3-kinase (PI3K) inhibitor. Activation of PI3K/Akt signaling pathway is frequently associated with tumorigenesis. Deregulation of this pathway occurs frequently with a variety of cancers and may contribute to the resistance to many anticancer agents. [1] Developing novel small molecules that specifically block the PI3K/Akt pathway may inhibit tumor growth. GDC-0941 is designed to bind the ATP-binding pocket of PI3K and to prevent formation of phosphatidylinositol-3, 4, 5-triphosphate (PIP3), a second messenger that transmits PI3K downstream signals. [2, 3] It binds to PI3K in an ATP-competitive manner.

GDC-0941 is a potent small-molecule thieno [3, 2-d] pyrimidine inhibitor of the class I PI3K. It is highly selective against isoforms p110( and p110( with IC50 of 3 nM, and moderately selective against isoforms p110( and p110( with IC50s of 33 nM and 75 nM, respectively.

GDC-0941 inhibits cell proliferation in vitro and in vivo. It causes growth inhibition in a variety of cancer cell lines, including A2780, MDA-MB-361, PC3, and U87MG. [2] It also inhibits the growth of trastuzumab–sensitive and –resistant HER2-amplied cancer cells which harbor p110( mutations or PTEN loss. [4] GDC-0941 also reduces tumor volume in different xenograft models. [4]

GDC-0941 can be taken orally.

References:
[1]Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene. 2008;27:5497-5510.
[2]Folkes AJ, Ahmadi K, Alderton WK, et al. The identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem. 2008; 51: 5522-5532.
[3]Knight ZA, Shokat KM. Chemically targeting the PI3K family. Biochem Soc Trans. 2007; 35: 245-249.
[4]Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Br J Cancer. 2011; 104(7): 1116-25.

文献引用

Chemical Properties

Physical AppearanceA solid
StorageStore at -20°C
M.Wt513.64
Cas No.957054-30-7
FormulaC23H27N7O3S2
Solubility≥25.7mg/mL in DMSO, ≥3.59 mg/mL in EtOH with ultrasonic and warming, <2.17 mg/mL in H2O
Chemical Name4-[2-(1H-indazol-4-yl)-6-[(4-methylsulfonylpiperazin-1-yl)methyl]thieno[3,2-d]pyrimidin-4-yl]morpholine
SDFDownload SDF
Canonical SMILESCS(=O)(=O)N1CCN(CC1)CC2=CC3=C(S2)C(=NC(=N3)C4=C5C=NNC5=CC=C4)N6CCOCC6
运输条件试用装:蓝冰运输。 其他可选规格:常温运输或根据您的要求用蓝冰运输。
一般建议为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。

试验操作

细胞实验[1]:

细胞系

Trastuzumab敏感和不敏感的HER2扩增细胞

制备方法

溶解度有限。若配制更高浓度的溶液,一般步骤如下:请将试管置于37℃加热10分钟和/或将其置于超声波浴中震荡一段时间。原液于-20℃可放置数月。

反应条件

2 h

实验结果

在所测试的所有细胞系中,250 nM GDC-0941处理2小时,抑制40%-85%的pAKT。GDC-0941还以剂量依赖性方式通过降低细胞增殖/活力来抑制PI3K/AKT途径。GDC-0941抑制trastuzumab敏感和不敏感的细胞生长。

动物实验[2]:

动物模型

U87MG人胶质母细胞瘤异种移植物

给药剂量

口服,每天75 mg/kg

实验结果

给药21天后,GDC-0941在不影响体重的情况下抑制83%肿瘤生长。剂量范围25-150 mg/kg/day的GDC-0941给药观察到剂量反应关系。GDC-0941还降低作为靶抑制指示剂的p-Akt水平。

注意事项

请于室内测试所有化合物的溶解度。虽然化合物的实际溶解度可能与其理论值略有不同,但仍处于实验系统误差的允许范围内。

References:

1. Junttila TT, Akita RW, Parsons K et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell. 2009 May 5;15(5):429-40.

2. Folkes AJ, Ahmadi K, Alderton WK et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer . J Med Chem. 2008 Sep 25;51(18):5522-32.

生物活性

描述 GDC-0941是一种有效的PI3Kα/δ抑制剂,IC50值为3 nM,对p110β (11倍)和p110γ (25倍)具有适度的选择性。
靶点 PI3Kα PI3Kβ PI3Kδ PI3Kγ    
IC50 3 nM 33 nM 3 nM 75 nM    

质量控制

化学结构

GDC-0941

相关生物数据

GDC-0941

相关生物数据

GDC-0941

相关生物数据

GDC-0941

相关生物数据

GDC-0941

相关生物数据

GDC-0941

相关生物数据

GDC-0941

相关生物数据

GDC-0941